Propylene Glycol USP/EP (Pharmacopeial-Grade Cosolvent Humectant Cryoprotectant Parenteral Vehicle) Storage

Propylene Glycol USP/EP (Pharmacopeial-Grade 1,2-Propanediol Cosolvent + Humectant + Cryoprotectant + Parenteral Vehicle) Storage — Compendial Propylene Glycol Tank Selection at Pharmaceutical, Compounding-Pharmacy, Sterile-Fill, and Cell-Therapy Cryopreservation Operations

Propylene Glycol USP (also called PG USP, propylene glycol USP, 1,2-propanediol, monopropylene glycol MPG, methyl glycol; CAS 57-55-6; molecular formula C₃H₈O₂; molecular weight 76.09 g/mol) is a clear, colorless, viscous, hygroscopic, slightly sweet diol meeting the USP-43-NF-38 Propylene Glycol monograph, the European Pharmacopoeia 11.0 Propylene Glycol monograph, and harmonized ICH Q3D + Q3C compendial requirements. Compendial pharmaceutical propylene glycol assays at 99.5% minimum, water content under 0.2% by Karl Fischer, residue on ignition under 0.005%, heavy metals under 5 ppm, chloride under 0.007%, sulfate under 0.006%, acidity under 0.4 mL of 0.1 N NaOH per 50 mL, and the critical USP <467> diethylene glycol (DEG) + ethylene glycol (EG) limit at under 0.10% each. The DEG/EG specification was sharpened across all pharmacopeial polyols (glycerin, propylene glycol, polyethylene glycols, sorbitol) after the 1996 Haitian acetaminophen + 2006 Panama cough-syrup + 2022 Gambia + Indonesia pediatric DEG mass-poisoning events.

Pharmaceutical USP propylene glycol functions as cosolvent + humectant + viscosity-modifier + cryoprotectant + parenteral vehicle across an exceptionally broad pharmaceutical formulation set: oral liquid pediatric + adult dosage forms, topical creams + lotions + transdermal patches, ophthalmic and otic preparations, parenteral injectable formulations (most notably as the principal vehicle in IV diazepam, lorazepam, etomidate, phenytoin sodium, esmolol, nitroglycerin), inhalation formulations (e-cigarette liquids, FDA-approved inhalation devices), vaccine adjuvant matrices, and cell-and-gene therapy + autologous + allogeneic cryopreservation programs. Physical properties: density 1.036 g/cm³ at 20°C; specific gravity 1.036; viscosity 56 cP at 20°C dropping to 13 cP at 50°C; flash point 99°C closed cup; autoignition 421°C; melting point -59°C; boiling point 188°C; fully water-miscible at all proportions; hygroscopic equilibrium 50-60% RH. Lower irritation profile than glycerin; better cosolvent power for hydrophobic APIs (cosolvent for diazepam, lorazepam, phenytoin, etoposide).

The eight sections below cite USP-NF 43, Ph. Eur. 11.0, FDA 21 CFR Parts 210 + 211 + 600-680, USP <467> Residual Solvents + DEG/EG Limit, USP <1116> Microbial Bioburden, ASME BPE-2022, FDA Guidance for Industry: Glycerin / Propylene Glycol Identity Testing for DEG (May 2007 + 2022 update), ICH Q7 + Q9 + Q10, and operating practice at Pfizer, Merck, GSK, Sanofi, Hospira (Pfizer), Fresenius Kabi, Baxter, ICU Medical, Eli Lilly, Bristol Myers Squibb, and similar large + mid-size pharmaceutical and CDMO operations for compendial propylene glycol storage and dispensing in oral, parenteral, ophthalmic, topical, biologic, and cryopreservation service envelopes.

1. Material Compatibility Matrix

Pharmaceutical USP propylene glycol is a chemically gentle aqueous-miscible diol with no oxidizer character, slightly acidic pH 6 in concentrate, no halogen or sulfur species, and no aromatic content. Material selection mirrors USP glycerin closely; PG's lower viscosity makes ambient-temperature pumping straightforward without tank heating.

The dominant industrial pattern at pharmaceutical manufacturing is two-stage: HDPE or XLPE rotomolded tanks at the bulk-receipt warehouse + compounding pharmacy ingredient warehouse for raw-material drum + tote + bulk-tanker receipt + short-term staging, then transfer through 316L electropolished sanitary piping to ASME BPE 316L formulation vessels for product-contact service. OneSource Plastics' 5-brand HDPE network (Norwesco, Snyder Industries, Chem-Tainer, Enduraplas, Bushman) covers the bulk-receipt + raw-material-warehouse + compounding-pharmacy + non-product-contact ingredient-storage envelope; ASME BPE 316L sanitary stainless tanks for product-contact formulation are outside the HDPE scope and we coordinate referral to qualified ASME BPE fabricators for sanitary stainless construction.

2. Real-World Industrial Use Cases

Parenteral Injectable Vehicle. USP propylene glycol is the principal cosolvent + vehicle in several iconic IV injectable formulations: IV diazepam (Valium injectable, 40% PG + 10% ethanol + 5% sodium benzoate vehicle); IV lorazepam (Ativan injectable, 80% PG + 18% ethanol + 2% benzyl alcohol vehicle); IV phenytoin sodium (Dilantin parenteral, 40% PG + 10% ethanol vehicle, pH 12); IV etomidate (Amidate, 35% PG vehicle); IV nitroglycerin (Tridil, 30% PG vehicle); IV esmolol (Brevibloc, PG-containing); IV pentobarbital (Nembutal, 40% PG + 10% ethanol vehicle). These formulations require pharmaceutical-grade PG with strict DEG/EG control and full compendial compliance because the formulation is administered intravenously at clinically meaningful PG dose loads; FDA + clinical literature has documented PG-induced lactic acidosis + hyperosmolality + renal injury at high cumulative doses (especially in pediatric ICU patients on continuous lorazepam infusion).

Oral Liquid Pediatric and Adult Dosage Forms. USP PG is the dominant cosolvent in oral liquid pharmaceutical preparations where API solubility requires a non-aqueous cosolvent: oral concentrate dexmedetomidine (Igalmi sublingual film), oral liquid prednisolone, oral risperidone (Risperdal Consta vehicle), oral methadone concentrate, OTC cough-cold preparations with low-water-soluble actives. Inclusion 5-50% w/v depending on API solubility requirements + formulation pH + organoleptic acceptability.

Topical and Transdermal Formulations. USP PG is the leading penetration enhancer + cosolvent + humectant in topical pharmaceutical preparations: hormonal transdermal patches (estradiol, testosterone, fentanyl, nicotine, scopolamine, clonidine), topical antifungal lotions (Lotrimin terbinafine), topical antibiotic creams (mupirocin, fusidic acid topical), topical retinoid preparations (tretinoin, tazarotene, adapalene), and dermatologic vehicle bases (lipid-cream PG-rich vehicles). Inclusion 5-50% w/w; functions as solvent + skin-penetration enhancer + viscosity modifier.

Cryopreservation in Cell-and-Gene Therapy. USP propylene glycol is increasingly used as alternative to DMSO in cryoprotectant cocktails for cell-therapy + autologous tissue + reproductive-medicine cryopreservation. Typical CPA formulations use 5-10% v/v PG combined with hydroxyethyl starch, sucrose or trehalose, and human serum albumin. PG offers reduced post-thaw cytotoxicity vs. DMSO at equivalent freezing-point depression. Reproductive-medicine cryopreservation (sperm, oocyte, embryo) uses PG-containing CPAs at 1.0-1.5 M PG concentrations; cell-therapy programs (CAR-T, NK-cell, MSC, iPSC) increasingly evaluate PG-substitution protocols to reduce DMSO-related infusion reactions.

Ophthalmic and Otic Preparations. USP PG is included in artificial-tear lubricant ophthalmic drops (Systane Ultra, Refresh Optive, Soothe XP) at 0.3-1.0% as demulcent + viscosity modifier; in ophthalmic anti-allergy and dry-eye prescription preparations as cosolvent. Otic preparations (Auro-Dri, Debrox carbamide peroxide) include PG as cosolvent + drying agent. Sterile + low-bioburden + low-endotoxin grade required for ophthalmic + otic use per USP <71> sterility + USP <85> bacterial endotoxins.

Inhalation and Vapor Products. USP PG is the primary humectant + aerosol-carrier in FDA-approved inhalation devices (selected nebulizer formulations + soft-mist inhalers) and the dominant carrier in nicotine vaping liquids + cannabis vape cartridges (where pharmaceutical-grade rather than tobacco-grade or technical-grade is required for FDA PMTA-pathway products). Inclusion 30-90% in vape liquids combined with vegetable glycerin USP, flavor compounds, and active.

Compounding Pharmacy Working Stocks. 503A + 503B compounding pharmacy operations stock USP PG in 1-pint to 55-gallon to 275-gallon IBC tote sizes for use in patient-specific oral, topical, and ophthalmic compounded preparations under USP <795> non-sterile + USP <797> sterile + USP <800> hazardous-drug compounding standards.

3. Regulatory Hazard Communication

OSHA HazCom GHS Classification. USP pharmaceutical propylene glycol is not classified as a GHS hazardous substance. Flash point 99°C placing it as Class IIIB combustible liquid per NFPA 30 (above 93°C); not flammable in normal handling. No GHS health hazard classifications at oral, dermal, or inhalation routes (extensive feeding-study + dermal + inhalation safety testing places PG at GRAS / Generally Recognized As Safe per FDA 21 CFR 184.1666 + 184.1666 + 21 CFR 184.1320). Environmental: rapidly biodegradable; fish LC₅₀ over 5000 mg/L. H-statements: none required. P-statements: P403+P233 Store in well-ventilated container kept tightly closed.

FDA cGMP Compliance Framework. Pharmaceutical USP propylene glycol used in finished drug products is regulated under 21 CFR Part 210 + 211 (finished pharmaceuticals) and 21 CFR Parts 600-680 (biologics) for raw-material identification, sampling, testing, retention, and disposition. Identity testing per 21 CFR 211.84(d)(2) requires at least one specific identity test on each container of PG received; FDA Guidance for Industry: Testing of Glycerin and Propylene Glycol for DEG (May 2007 reaffirmed 2022) mandates the USP <467> DEG + EG limit test on every container of PG used in finished drug products to prevent recurrence of mass-poisoning events. The 2022 Indonesia pediatric DEG fatalities + Gambia 2022 + 1996 Haiti + 2006 Panama events all involved DEG-contaminated polyols (glycerin + PG) substituted for or adulterated with diethylene glycol by upstream chemical-distributor fraud.

USP-NF 43 Compendial Specifications. Pharmacopeial harmonized PG specifications: assay 99.5% minimum; identification by IR spectrum + refractive index 1.431-1.433 at 20°C + specific gravity 1.035-1.037; water content under 0.2% by Karl Fischer; residue on ignition under 0.005%; heavy metals under 5 ppm; chloride under 0.007%; sulfate under 0.006%; acidity under 0.4 mL of 0.1 N NaOH per 50 mL; DEG + EG each under 0.10% per USP <467>; ICH Q3D elemental impurities (As, Cd, Hg, Pb under PDE limits for parenteral/oral routes); ICH Q3C residual solvents (Class 1 + Class 2 limits); microbial limits per USP <61> + <62> appropriate for intended route of administration.

DOT and Shipping. USP propylene glycol is not regulated under 49 CFR DOT Hazardous Materials Regulations at any concentration. No UN number, no hazard class, no packing group. Shipped as standard non-hazardous liquid in HDPE drums (5-30-55-gallon), HDPE 275-330-gallon IBC totes, and stainless or HDPE-lined tank trucks at bulk pharmaceutical-feedstock movements.

EPA Air Regulations. PG storage tanks not subject to 40 CFR Part 60 NSPS Subpart Kb (vapor pressure 0.08 mmHg at 20°C far below 0.75 psi threshold); not subject to Subpart K, KKK, or similar air regulations. Pharmaceutical manufacturing facilities are subject to 40 CFR Part 63 Subpart GGG Pharmaceuticals Production NESHAP for organic HAP emissions; PG is not a HAP and not a regulated air emission source.

FDA GRAS Status. Propylene glycol holds GRAS status per 21 CFR 184.1666 (direct human food additive affirmed GRAS), 184.1666(c) (limited to specific food categories at maximum levels), and 582.1666 (animal feed). Used as humectant + solvent + emulsifier + flavor carrier + dough strengthener at FDA-prescribed maximum-use levels by food category. Pharmaceutical inclusion is unrestricted under cGMP framework with cumulative-dose-of-formulation-vehicle clinical safety considerations driving formulation design.

4. Storage System Specification

Bulk-Receipt and Raw-Material-Warehouse Storage. Pharmaceutical USP propylene glycol arrives at the manufacturing facility raw-material warehouse via 5-gallon pails, 55-gallon HDPE drums, 275-330-gallon HDPE IBC totes, or stainless / HDPE-lined tank trucks (4500-6500 gallon delivery). Bulk-tanker deliveries at large pharmaceutical operations transfer to dedicated bulk-receipt storage tanks: HDPE rotomolded vertical 1500-15000-gallon vessels, FDA-grade HDPE-blend per 21 CFR 177.1520 with sanitary 4-inch BSP tank-top fill, 4-inch ANSI bottom flanged outlet, atmospheric vent with inline 0.2-micron sterilizing-grade hydrophobic vent filter, tank-mounted level transmitter (radar or guided-wave), and ambient-temperature handling without tank heating (PG viscosity 56 cP at 20°C is comfortably pumpable without warming).

Tank Sizing. Typical bulk-receipt tank sizes: 1500-3000 gallons at compounding pharmacies + small-batch sterile-fill operations; 5000-10000 gallons at mid-size pharmaceutical manufacturing; 15000-30000 gallons (multiple HDPE tanks in parallel manifold) at large-scale parenteral-fill + topical-formulation + inhalation + biologic operations. Tank sizing accounts for typical 30-day forward-stock requirement plus 2-week safety stock plus delivery cadence.

Compounding Pharmacy Working-Stock Storage. Compounding pharmacies + 503A + 503B operations stock PG USP in 5-30 gallon HDPE drums at the ingredient warehouse + sterile compounding anteroom + non-sterile compounding cleanroom. Drum + tote receiving uses HDPE-pump dispensing into smaller working stocks; working stocks at the compounding bench dispensed from FDA-grade HDPE bottles or USP-spec amber-glass.

Product-Contact Formulation Tanks. Active formulation + compounding for finished oral / topical / ophthalmic / parenteral / biologic preparations occurs in 316L electropolished sanitary stainless tanks per ASME BPE-2022 with internal surface finish Ra under 0.5 microns, all-welded 316L sanitary tri-clamp transfer piping, BPE diaphragm or ball valves, jacketed temperature control, top-mounted impeller agitation, CIP/SIP capability via spray-ball + steam-trap installation, and validated cleaning + steam-in-place cycles. These vessels are outside the HDPE network and not OneSource scope.

Secondary Containment. Bulk-receipt HDPE storage vessels at pharmaceutical operations are placed inside HDPE secondary-containment pans sized to 110% of largest single tank capacity per facility-wide containment best-practice extending EPA SPCC 40 CFR Part 112 discipline to all bulk liquid storage even when not formally an oil + not a CERCLA hazardous substance.

Inert-Gas Blanketing. Pharmaceutical-grade PG bulk storage at high-end sterile-fill + parenteral-vehicle operations may include nitrogen blanketing of the tank vapor space to minimize peroxide formation + microbial ingress at long-term storage. Atmospheric venting through 0.2-micron sterilizing-grade hydrophobic filter is the dominant pattern; nitrogen blanketing is an upgrade at high-purity parenteral-vehicle service.

5. Field Handling Reality

Operator PPE. Pharmaceutical operators handling USP propylene glycol require standard pharmaceutical manufacturing PPE: cleanroom-grade gowning at sterile + cleanroom operations (Tyvek IsoClean or equivalent disposable cleanroom suit, hood, mask, latex or nitrile inner + outer gloves, sterile boot covers, goggles + face shield), safety glasses + lab coat + closed-toe shoes at non-cleanroom ingredient warehouse + bulk-receipt operations, nitrile gloves at all liquid-handling operations to prevent product cross-contamination. Spill-response gear at the bulk-receipt area. No respirator required at any handling temperature; no splash-shield required beyond standard safety glasses.

Microbial Bioburden Control. Concentrated USP propylene glycol (under 0.2% water) is microbiostatic + self-preserving against bacterial + mold growth. Diluted aqueous PG solutions (under 60% w/w) lose self-preservation and require either microbial preservation (parabens, phenoxyethanol, sorbate, benzoate) or sterile-filtered + closed-system handling. Bulk-receipt + warehouse storage of concentrated USP PG does not require preservative addition; dilution into formulation triggers the preservation framework per USP <51> antimicrobial effectiveness testing.

Spill Response. PG spill response at pharmaceutical manufacturing facilities is a low-hazard standard cleanup: (1) deploy absorbent pads or floor-sweep granular absorbent (vermiculite, diatomaceous earth, water-based sorbent), (2) collect into double-bagged poly waste for pharmaceutical-waste profiling and disposal under facility-specific waste streams (typically non-RCRA, non-hazardous), (3) wash spill area with hot water + mild detergent (PG's high water-solubility makes water + detergent the appropriate decontamination route; concrete sealants and floor coatings require post-spill inspection for slip hazard from residual PG film), (4) document spill volume + decontamination + containment integrity for the facility deviation + investigation system per 21 CFR 211.192.

Slip Hazard. PG's low coefficient of friction on hard floors creates a meaningful slip hazard at any bulk-receipt drum-handling + tote-handling + tank-fill operation. Slip-resistant floor mats + secondary containment + floor cleaning protocols are essential at the bulk-receipt staging area; pharmacy + manufacturing facility safety programs include PG spill in the standard slip-trip-fall hazard inventory under OSHA 29 CFR 1910.22 General Walking-Working Surfaces and OSHA 29 CFR 1910 Subpart D housekeeping requirements.

Decontamination of Cross-Contamination Spills. Pharmaceutical manufacturing under 21 CFR 211.42 + 21 CFR 211.46 + 21 CFR 211.67 cleaning + cross-contamination prevention requires documented cleaning of any spill area + adjacent equipment + drains + transfer-piping returning to compendial-clean status. PG spill at a multi-product compounding bench triggers cross-contamination investigation, equipment-cleaning verification, and quality-deviation closure before resumption of compounding.

Clinical Awareness of Cumulative Dose Toxicity. Operators at injectable-pharmaceutical manufacturing should be aware that PG-vehicle injectable formulations administered at high cumulative doses (especially pediatric ICU continuous lorazepam infusion, IV phenytoin loading, IV nitroglycerin extended infusion) have been associated with PG-induced lactic acidosis, hyperosmolar metabolic disturbances, and renal injury in clinical literature. Manufacturing-side QC + lot-traceability + DEG/EG verification + assay-confirmation are critical barriers to product-quality + patient-safety failure modes.

Talk to OneSource Plastics

Listed price covers tank + standard fitting package; LTL freight is quoted separately to your delivery ZIP. Call 866-418-1777, use our freight estimator, or try our chemical tank recommender to narrow material selection.